Who regulates medicines: AIRP, not the old DPML
Medicines in Côte d'Ivoire are regulated by the Autorité Ivoirienne de Régulation Pharmaceutique (AIRP), the Ivorian Pharmaceutical Regulation Authority. Law n° 2017-541 of 3 August 2017 created it, and décret n° 2018-926 of 12 December 2018 sets out its organisation, including one directorate for the registration of pharmaceutical products and another for inspection and market surveillance.
Older guides and supplier files still name the Direction de la Pharmacie, du Médicament et des Laboratoires (DPML), the former ministry directorate. Article 40 of the decree says acts issued by that directorate stay valid until they expire. Import authorisations are now issued by AIRP under its own decision, so your importer should address new paperwork to AIRP.
Côte d'Ivoire is one of the eight member states of UEMOA, the West African Economic and Monetary Union. UEMOA sets the common registration procedure in Règlement n° 04/2020/CM/UEMOA, but each member state issues its own national AMM (autorisation de mise sur le marché, the marketing authorisation). An AMM from Senegal or Mali is therefore not an Ivorian AMM, although the regulation lets one member state refer to the technical evaluation of another. Read our Côte d'Ivoire market page and the wider Africa overview for the commercial picture.
Two permissions: the AMM and the import authorisation
An Indian-made medicine needs two separate permissions, and having one does not give you the other.
- The AMM for the product. The UEMOA regulation says no pharmaceutical product for human use may be put on the market, free or for payment, in a member state without a prior AMM (Article 7).
- The prior import authorisation for each shipment. AIRP decision n° 0005/AIRP/DG of 17 February 2025 says every import or export of a pharmaceutical product needs a prior authorisation from AIRP, which it calls the Autorisation Préalable à l'Importation (API).
The decision adds that this authorisation is issued only to establishments approved by AIRP. It can be used once, it is in a named holder's name, it cannot be transferred, and it carries fees set by AIRP. The decision does not say in so many words who files the request, but since only an AIRP-approved establishment can hold the authorisation, check that your buyer is one before you commit to a price or a shipping date.
Two points the decision leaves to other texts. Article 6 says the processing time and the validity period of authorisations are set in guidelines annexed to the decision, and Article 7 says the entry and exit points for pharmaceutical products are those AIRP defines with the customs administration. The copy of the decision we read has no annex attached, so ask your importer for the current time limit and the permitted border points before you plan a shipment.
How the AMM is processed and how long it takes
The steps below come from Règlement n° 04/2020/CM/UEMOA of 28 September 2020, which repeals and replaces Règlement n° 06/2010, and from its annexes.
- The AMM application goes to the national authority, here AIRP, with the receipt for the registration fees (Article 8). The dossier has an administrative Module 1 and technical Modules 2 to 5 in CTD format.
- The authority checks completeness. The annexes say incomplete dossiers are not received, and a filing receipt is issued on reception. A dossier found inadmissible is notified to the applicant, who gets three months to complete it.
- A committee of experts assesses the dossier, then the Commission Nationale du Médicament (national medicines commission) validates it against the criteria in the regulation (Article 11).
- The authority notifies the decision. A refusal is notified within 30 working days of the commission session (Article 20).
The annexes say a new AMM takes at least 120 days and no more than 360 days, and that the clock stops while the applicant answers questions. An AMM is valid for five years (Article 16), and the renewal application is filed 120 days before expiry (Article 19). Renewal also needs the batch record of a real batch made within six months before filing, and the periodic safety update reports.
Fees: décret n° 2015-602 of 2 September 2015 makes the applicant pay a base fee when the initial application is filed, charged for each dosage form and each presentation, so a range with several forms and pack sizes costs more to register. We have not confirmed that the decree's amounts are still current, so ask your importer for AIRP's present schedule.
Dossier language, documents and samples
The UEMOA annexes set a language rule for one part of the dossier: Module 1, the administrative module, must be submitted in the official language of the country, and where documents are translated, the applicant answers for the accuracy of the translation. The annex text we read sets no such rule for Modules 2 to 5, which hold the summaries and the quality, non-clinical and clinical data. Every AIRP text we read is written in French, so plan Module 1 in French and ask AIRP what it accepts for the other modules.
Besides the dossier, the annexes ask the applicant for the following.
- Sale-model samples from a batch of the product, with batch analysis certificates. The annexes give an indicative table of sample numbers by product type, and the samples must have an expiry date at least 18 months away.
- A Certificate of Pharmaceutical Product in the WHO format, issued by the medicines authority of the country of origin or manufacture.
- A site master file of the factory that made the product.
Module 1 also covers GMP status. The annexes say the GMP compliance status issued by other regulators, with the date of the last GMP inspection, goes in the administrative module. The AMM itself is issued to a legal entity (Article 14, first paragraph). The texts we read do not say that this entity must be incorporated in Côte d'Ivoire, so settle with AIRP and your importer who will file before the dossier is assembled.
Reliance routes: when AIRP can lean on another regulator
AIRP decision n° 0014 of 1 September 2025 replaces decision n° 0004 of 13 February 2025 on regulatory reliance. It lets AIRP rely on certificates, reports or decisions from authorities with at least WHO maturity level 3, from WHO Listed Authorities, from ICH members, from PIC/S member authorities, and from bodies such as WHO, the African Medicines Agency, WAHO and UEMOA. Reliance applies to the registration of pharmaceutical products among other functions, and AIRP stays fully independent and responsible for its own decisions.
The AIRP reliance guideline we read, version 01, carried a version expiry date of 31 December 2025, which has passed. We found no replacement, so the figures below may have been revised; confirm them with AIRP. The guideline says reliance works only if the product is essentially the same as the one the reference authority assessed, with the manufacturer confirming this and supplying uniform documents apart from country-specific items such as climatic-zone stability data and labelling. For a WHO-prequalified product under the collaborative procedure, it says AIRP decides within 90 days, with time given to the applicant not counted, and informs the applicant within 30 further days. The French wording of the 90-day step is ambiguous about when the count starts. For active ingredients, it accepts a European CEP or WHO active-substance prequalification as proof of quality.
Separately, AIRP decision n° 0007 of 19 February 2025 allows AIRP, as an exception, to authorise the use of certain products that have no AMM in Côte d'Ivoire. Our note on WHO prequalification versus national registration explains when each route pays off.
Importing a consignment once the AMM exists
Once a product has an AMM, each shipment still needs its own API. Because the authorisation is used once and is in the holder's name, a second shipment or a different importer needs a fresh authorisation rather than a reused one.
Plan your paperwork around that. Ask the importer for a copy of the API before you load, because decision n° 0005 requires the authorisation before the import takes place. Match the invoice, the packing list and the batch documents to the product and the holder named in the approval. Agree in the contract who bears the cost if a consignment arrives without a valid approval.
For goods with no AMM, the second paragraph of Article 14 of the UEMOA regulation lets the competent authority grant a special import authorisation on an exceptional basis for public health reasons, and decision n° 0005 describes a special and provisional import authorisation only in cases of public health emergency. Either way the shipment still needs an AIRP authorisation before it arrives, because decision n° 0005 covers the import of any pharmaceutical product. Treat these as exceptions the importer must justify to AIRP, not as a regular supply line. For public and hospital buyers, our government supply services and NGO procurement pages explain how we support tender supply.
What M Care Exports prepares from India
M Care Exports is an Indian merchant exporter. It sources from WHO-GMP and EU-GMP certified manufacturers and does not manufacture, so the regulatory evidence comes from the manufacturing site and its authority. M Care Exports assembles it into a filing pack and checks it against the UEMOA annexes.
- CTD dossier documents for each product, with the Module 1 papers set out so your translator can work from them.
- The manufacturer's GMP status, the Certificate of Pharmaceutical Product and the site master file, collected from the manufacturer and the issuing authority and checked for dates and product names.
- Sale-model samples with batch certificates and an expiry date at least 18 months away.
- Pack and leaflet artwork that matches the approved text, so the shipped goods match the AMM.
M Care Exports also coordinates the importer's paperwork, so the invoice, packing list and batch documents agree with the API, and it ships from India once your importer holds the approval. Our CTD dossier preparation service covers the first part. Before you appoint any supplier, read our due diligence guide, then request a medicine and tell us the molecule, strength and quantity.
Frequently asked
Can we register an Indian generic in Côte d'Ivoire without a local company?
The UEMOA regulation says an AMM is issued to a legal entity (Règlement 04/2020, Article 14), and each member state issues its own national AMM (Article 15). The texts we read do not say the entity must be Ivorian and name no local-agent rule, so ask AIRP who may file before you build the dossier. M Care Exports assembles the dossier documents from the manufacturer and works with your importer or chosen applicant so the filing is complete when it reaches AIRP.
We are an importer. Do we need an AMM and a separate import permit for each shipment?
Yes, on the texts. Règlement 04/2020 Article 7 bars any product from the market without an AMM. AIRP decision n° 0005 of 17 February 2025 requires a prior import authorisation, the API, issued only to AIRP-approved establishments, usable once, in a named holder's name and not transferable. So the AMM covers the product and each shipment needs its own API. M Care Exports ships from India once your API is in hand and keeps the invoice and batch documents consistent with it.
How long does it take to get an AMM in Côte d'Ivoire?
The annexes to Règlement 04/2020 say a new AMM takes at least 120 days and no more than 360 days, with the clock stopped while the applicant answers questions. That is the legal frame, not a promise of speed, and incomplete dossiers are not received at all. The AMM lasts five years, and renewal is filed 120 days before expiry. M Care Exports checks the dossier for completeness before filing and tracks the renewal date so your product does not lapse.
Does the whole dossier have to be in French?
Not on the annexes we read. They require Module 1 in the official language of the country, make the applicant answer for the accuracy of any translation, and set no language for Modules 2 to 5. AIRP writes its own texts in French, so plan Module 1 in French and ask AIRP what it accepts for the rest. M Care Exports gathers the source documents from the manufacturer and works with your translator so the Module 1 text matches the approved product information.
Can a WHO-prequalified or reference-authority product register faster?
Possibly. AIRP decision n° 0014 of 1 September 2025 lets AIRP rely on WHO, WHO Listed Authorities, ICH members and other bodies for registration, while AIRP stays responsible for its decision. Its reliance guideline says AIRP decides within 90 days under WHO's collaborative procedure, with applicant time not counted, but that guideline version carried an expiry date of 31 December 2025, so confirm the current terms with AIRP. M Care Exports checks whether the manufacturer holds the approval you would rely on and prepares the sameness documents.
We need an urgent supply of a medicine with no AMM. Is there a route?
Only by exception. Règlement 04/2020 Article 14 allows a special import authorisation, exceptionally and for public health reasons, and AIRP decision n° 0007 of 19 February 2025 allows exceptional authorisations to use products with no AMM. Decision n° 0005 limits its special and provisional import authorisation to public health emergencies, and the shipment still needs AIRP's authorisation before import. The importer must justify the request to AIRP. M Care Exports can supply the product and the technical documents your importer needs for it.
Who pays the registration fees and how much are they?
The applicant pays. Règlement 04/2020 Article 8 says the application carries the fee payment receipt, and décret n° 2015-602 of 2 September 2015 sets a base fee at the initial filing, charged per dosage form and per presentation. We have not confirmed that the decree's amounts are AIRP's current schedule, so we do not quote them here. Ask AIRP or your importer for the present figures. M Care Exports lists each form and pack size in your product plan so you can count the fees before filing.
Official sources
The regulators and official documents to check this guide against. Requirements change, so confirm the current version with the regulator before you file.
- AIRP: décision n° 0005/AIRP/DG du 17 février 2025, conditions d'importation et d'exportation des produits pharmaceutiques (PDF)
- AIRP: décision n° 0014/AIRP/DG du 1er septembre 2025, modifiant et abrogeant la décision n° 0004 du 13 février 2025 portant confiance réglementaire et/ou reconnaissance (PDF)
- AIRP: décision n° 0007/AIRP/DG du 19 février 2025, conditions de dérogation de l'autorisation de mise sur le marché (PDF)
- AIRP: Exigences en matière de gestion de la reconnaissance / confiance réglementaire, ligne directrice AIRP-LD-7.5-03.2-02, version 01 (PDF)
- UEMOA: Règlement n° 04/2020/CM/UEMOA du 28 septembre 2020, procédures d'homologation des produits pharmaceutiques à usage humain (PDF)
- UEMOA: annexes au Règlement n° 04/2020/CM/UEMOA (PDF)
- Côte d'Ivoire: décret n° 2018-926 du 12 décembre 2018, organisation et fonctionnement de l'AIRP, JORCI du 14 mars 2019 (PDF)
- Côte d'Ivoire: décret n° 2015-602 du 2 septembre 2015, redevances pour l'autorisation de mise sur le marché des médicaments (PDF)
Send the specifics. We will scope it honestly.
Molecule, strength, volume and destination. The Mumbai desk replies within one working day, including when the answer is that the route is not viable yet.
